Biopolym. Cell. 1990; 6(2):24-31.
http://dx.doi.org/10.7124/bc.000255
Transgenic rats expressing human growth hormone gene as a model of some types of diabetes
1Ignatieva T. V., 1Golinsky G. F.
  1. Institute of Experimental Medicine, Academy of Medical Sciences of the USSR
    Leningrad, USSR

Abstract

The human growth hormone gene with promoter of rat tyrosine aminotranspherase or promoter of mouse metallothioneine 1 was used for producing transgenic rats. The method was developed to introduce these genes into the rat genome. The expression of the human growth hormone genes was observed in transgenic rats. The level of the human growth hormone in blood was much higher/about 80 ng/ml/ than in the control rats. One group of transgenic rats grew quicker and the other — slower as compared to the control. The tolerance to glucose decreased in the transgenic rats and the pancreatic islets experienced some degenerative changes. The transgenic rats with the human growth hormone gene can be used as a biological model of diabetes.
Full text: (PDF, in Russian)

References

[1] Mills JL. Malformations in infants of diabetic mothers. Teratology. 1982;25(3):385-94.
[2] Eriksson UJ, Karlsson MG, Styrud J. Mechanisms of congenital malformations in diabetic pregnancy. Biol Neonate. 1987;51(2):113-8. Review.
[3] Farrell PM, Engle MJ, Frantz ID, Goldman AS, Kalkhoff R, Kemnitz JW, Perelman R, Stern JS, Susa JB. Complications of pregnancy and fetal development. Diabetes. 1982;31(Suppl 1 Pt 2):89-94.
[4] Baird JD, Aerts L. Research priorities in diabetic pregnancy today: the role of animal models. Biol Neonate. 1987;51(2):119-27.
[5] Eriksson U, Dahlström E, Larsson KS, Hellerström C. Increased incidence of congenital malformations in the offspring of diabetic rats and their prevention by maternal insulin therapy. Diabetes. 1982;31(1):1-6.
[6] Shaw Dunn J, Mcletchie NGB. Experimental alloxan diabetes in the rat. The Lancet. 1943;242(6265):384–7.
[7] Rakieten N, Rakieten ML, Nadkarni MV. Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother Rep. 1963;29:91-8.
[8] Conge GL, Gouache P, Lagratice P. H. Cell-mediated immune response in diabetic mice. Nutr Reports Int. 1982:443-50.
[9] Williams DA, Orkin SH. Somatic gene therapy. Current status and future prospects. J Clin Invest. 1986;77(4):1053-6.
[10] Lin T. P. Egg micromanipulation. Meth . in mammalian embryology. San-Francisco, 1971:157-71.
[11] Vaysman BL, Golinskiy GF. Technique of microinjection of cloned DNA fragments (foreign genes) into mouse feminonucleus. General patterns and control mechanisms of early embryogenesis of mammals in normal and pathological. Ed. AP Dyban. Leningrad, Medicine, 1985; 108-13.
[12] Sekirina GG. Cultivation technique of pre-implantation mouse embryos. General patterns and control mechanisms of early embryogenesis of mammals in normal and pathological. Ed. AP Dyban. Leningrad, Medicine, 1985; 114-23
[13] Kabak YaM. Workshop on endocrinology. Basic techniques of experimental and endocrinology research. Moscow, University Press, 1968; 146.
[14] Hammer RE, Palmiter RD, Brinster RL. Partial correction of murine hereditary growth disorder by germ-line incorporation of a new gene. Nature. 1984 Sep 6-11;311(5981):65-7.
[15] GorodetskiÄ­ SI, Dyban AP, VaÄ­sman BL, GolinskiÄ­ GF, Popkova GA. Stimulation and inhibition of the growth of mice carrying the human growth hormone gene. Biull Eksp Biol Med. 1986;102(9):339-42.